Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Receivables (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Receivables for 12 consecutive years, with $232298.0 as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 89.94% to $232298.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $232298.0, a 89.94% increase, with the full-year FY2025 number at $204873.0, up 115.94% from a year prior.
  • Receivables was $232298.0 for Q4 2025 at Regen BioPharma, up from $204873.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $295466.0 in Q2 2022 to a low of $12298.0 in Q4 2023.
  • A 5-year average of $156991.9 and a median of $158042.0 in 2021 define the central range for Receivables.
  • Peak YoY movement for Receivables: plummeted 90.66% in 2023, then skyrocketed 894.45% in 2024.
  • Regen BioPharma's Receivables stood at $240617.0 in 2021, then plummeted by 45.27% to $131698.0 in 2022, then tumbled by 90.66% to $12298.0 in 2023, then surged by 894.45% to $122298.0 in 2024, then soared by 89.94% to $232298.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Receivables are $232298.0 (Q4 2025), $204873.0 (Q3 2025), and $177147.0 (Q2 2025).